Next Article in Journal
Correction: Chang et al. Intertypic Recombination Between Coxsackievirus A16 and Enterovirus A71 Structural and Non-Structural Genes Modulates Virulence and Protection Efficacy. Vaccines 2025, 13, 1017
Previous Article in Journal
Impact of the 2023/24 Influenza Vaccination on Patients with Inflammatory Rheumatic Disease in Germany: Insights from a Nationwide, Longitudinal, Self-Reported Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 14
Issue 2
10.3390/vaccines14020138
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

AddaVax, AddaS03, and Alum Effectively Enhance Cross-Reactive and Cross-Neutralizing Antibody Responses Against SARS-CoV-2 Induced by the Inactivated NDV-HXP-S Vaccine in Mice

by
José Luis Martínez-Guevara
1,
Tsoi Ying Lai
1,
Mitali Mishra
1,
Stefan Slamanig
1,2,
Irene González-Domínguez
1,
Adam Abdeljawad
1,
Minh Thu Hoang
1,
Gagandeep Singh
1,3,
Shreyas Kowdle
1,
Benhur Lee
1,
Florian Krammer
1,3,4,5,6,
Peter Palese
1,7 and
Weina Sun
1,*
1
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
2
Swammerdam Institute for Life Sciences, University of Amsterdam, 1012 WP Amsterdam, The Netherlands
3
Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
4
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
5
Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, 1090 Vienna, Austria
6
Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness at the Medical University of Vienna, 1090 Vienna, Austria
7
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
*
Author to whom correspondence should be addressed.
Vaccines 2026, 14(2), 138; https://doi.org/10.3390/vaccines14020138
Submission received: 24 December 2025 / Revised: 18 January 2026 / Accepted: 23 January 2026 / Published: 29 January 2026
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Browse Figures
Versions Notes

Abstract

Background/Objectives: We previously developed a low-cost vaccine based on Newcastle disease virus expressing a stabilized pre-fusion spike of SARS-CoV-2 (NDV-HXP-S), which has shown safety and immunogenicity in pre-clinical and clinical studies. Due to the emergence of immune-evasive variants and the need to protect vulnerable populations, we evaluated adjuvanted NDV-HXP-S vaccine formulations to enhance and broaden immune responses. Methods: We tested the antibody responses of mice immunized intramuscularly with an inactivated NDV-HXP-S vaccine adjuvanted with AddaVax, AddaS03, Alhydrogel adjuvant 2% (Alum), or Quil-A. Results: AddaVax, AddaS03, and Alum induced the strongest IgG responses to the ancestral spike protein, boosted cross-reactive antibodies against both S1 and S2 subunits, and elicited high cross-neutralizing titers. Conclusions: The present results highlight the critical role of adjuvant selection in shaping both the magnitude and breadth of the immune response induced by the NDV-HXP-S vaccine. AddaVax, AddaS03, and Alum stand out as promising candidates to enhance NDV-HXP-S vaccine immunogenicity, with potential applications in booster strategies against SARS-CoV-2, enabling dose sparing and reducing costs.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and rapidly spread worldwide, causing a pandemic with great health, social, and economic impacts [1,2,3]. In response to this challenge, multiple vaccines were developed targeting the viral spike glycoprotein located on the surface of the virus, which mediates entry into host cells. The spike consists of two subunits, S1 and S2, separated by a polybasic S1/S2 cleavage site [4,5] (Figure 1). Within S1, two major antigenic regions are critical for viral infection and vaccine immune recognition: the receptor-binding domain (RBD) and the N-terminal domain (NTD). RBD binds to the cellular angiotensin-converting enzyme 2 (ACE2) receptor during viral entry [5,6] and is the primary target for neutralizing antibodies that prevent the virus attachment to the host cell [7,8,9,10], whereas NTD contributes to spike protein stability and is also an important target of neutralizing antibodies [5,7,9,11] (Figure 1).
We previously developed a SARS-CoV-2 vaccine using Newcastle disease virus (NDV) as a vector to express a stabilized pre-fusion spike protein. Stabilization was achieved by removing the S1/S2 cleavage site and introducing six proline substitutions in S2 (F812P, A892P, A899P, A942P, K986P, and V987P) (Figure 1) [12]. This hexapro-spike (HXP-S) is anchored in the membrane of the NDV virion by replacing the SARS-CoV-2 spike transmembrane domain and cytoplasmic tail with those from the NDV fusion (F) protein. Finally, the transgene is inserted between the phosphoprotein and the matrix genes of NDV [12]. Pre-clinical studies have shown that the NDV-HXP-S vaccine, either live or inactivated, elicits robust humoral and cellular immunity and provides protection in various animal models [12,13,14,15,16,17,18]. Clinical trials conducted in the US (NCT05181709), Thailand (NCT04764422), Vietnam (NCT04830800), Brazil (NCT04993209), and Mexico (NCT04871737) have demonstrated that this vaccine is safe and highly immunogenic in humans [19,20,21,22], leading to emergency approval of an inactivated NDV-HXP-S vaccine in Thailand (HXP-GPOVac, produced by Thailand’s government Pharmaceutical Organization (GPO)) [23] and a live NDV-HXP-S vaccine in Mexico (Patria, developed by Avimex) [24].
Although effective, the NDV-HXP-S vaccine still must be adapted to emerging SARS-CoV-2 variants of concern (VOCs), which are capable of escaping vaccine-elicited immune responses. Immune escape by VOCs is largely driven by mutations in the immunodominant RBD of the spike, which have led to substantial reductions in neutralization by both vaccine-induced and infection-induced antibodies [25,26,27,28,29].
Given the strong immune pressure on the RBD, immunization strategies that redirect antibody responses toward epitopes less affected by RBD mutations are needed to achieve durable and broad protection. In this context, the NTD, a target of potent neutralizing antibodies [30,31,32], and the more conserved S2 subunit, which elicits broadly cross-reactive antibodies across divergent variants [33,34], represent promising targets for enhancing cross-protective immunity.
To broaden vaccine protection, we previously demonstrated that a multivalent vaccine formulation incorporating NDV-HXP-S viruses expressing the spike from the ancestral, Beta, and Delta variants increased cross-neutralization against phylogenetically distant VOCs [13,17], thereby improving the breadth of protection conferred by the NDV-HXP-S vaccine. Another strategy to improve cross-protection is the use of adjuvants. However, it remains unclear which adjuvant best enhances and broadens the immune response elicited by the NDV-HXP-S vaccine. In this study, we evaluated the antibody responses elicited by an inactivated NDV-HXP-S vaccine administered with different adjuvants.
We evaluated two oil-in-water nanoemulsions: AddaVax, which has a similar formulation to that of MF59, and AddaS03, with a composition resembling the adjuvant system 03 (AS03). MF59 and AS03 have both been employed in Europe as adjuvants in influenza vaccines [35,36,37,38,39,40]. Additionally, we tested Alhydrogel adjuvant 2% (Alum), an aluminum hydroxide wet gel suspension widely used in human vaccines [41,42], and Quil-A, a plant-derived extract from the tree Quillaja saponaria, composed of a mixture of over 100 different saponins [43,44,45]. Currently, Quil-A is restricted to veterinary vaccines [46,47], but a purified fraction from this adjuvant, designated as QS-21, is a component of commercial vaccines against shingles, malaria, and SARS-CoV-2 [48].
Vaccine adjuvants represent a powerful strategy to modulate both the magnitude and epitope specificity of antibody responses. Oil-in-water emulsions such as MF59 and AS03 (and their analogs AddaVax and AddaS03) enhance immune responses primarily by promoting local innate immune activation, increasing antigen uptake, and facilitating recruitment and differentiation of antigen-presenting cells at the injection site and draining lymph nodes [35,40,49]. Alum acts through the formation of an antigen depot, enabling sustained release, inflammasome activation, and has been associated with strong Th2-biased humoral responses [50,51,52]. In contrast, saponin-based adjuvants such as Quil-A and its purified derivative QS-21 stimulate immunity through inflammasome activation and enhanced cross-presentation, often favoring a sustained Th1-type activation [47,53]. However, the extent to which these adjuvant classes differentially shape epitope targeting and cross-variant antibody breadth in the context of NDV-based SARS-CoV-2 vaccines is unknown.
We found that AddaVax, AddaS03, and Alum significantly enhanced cross-reactive IgG responses to both the S1 and S2 subunits of different SARS-CoV-2 variants when combined with the inactivated NDV-HXP-S vaccine, with Alum being the most effective at boosting antibodies against S2 and the NTD. Importantly, AddaVax, AddaS03, and Alum increased cross-neutralizing antibody titers against diverse VOCs. In contrast, Quil-A also enhanced some antibody responses against the spike, but to a lesser extent.

2. Materials and Methods

2.1. Cells, Proteins, and Adjuvants

Baby hamster kidney cells stably expressing human ACE2 (BHK-hACE2) were cultured at 37 °C with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher Scientific, Waltham, MA, USA; Cat# 11995-065) supplemented with 10% (v/v) of heat inactivated fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA; Cat# 10437-028), and 100 units/mL of penicillin plus 100 μg/mL of streptomycin (Pen Strep) (Thermo Fisher Scientific, Waltham, MA, USA; Cat# 15140122).
Full-length SARS-CoV-2 ancestral spike and the RBD domains for the ancestral, Beta, Delta, and BA.1 variants were produced as described previously [54,55]. The S1 subunit, S2 subunit, and the NTD proteins of the different variants were obtained from ACROBiosystems (Newark, DE, USA) (Table 1).
AddaVax (Cat# vac-adx), AddaS03 (Cat# vac-as03), Alhydrogel adjuvant 2% (Cat# vac-alu), and Quil-A (Cat# vac-quil) were obtained from InvivoGen (San Diego, CA, USA).

2.2. NDV-HXP-S Virus Propagation

The NDV-HXP-S ancestral virus was previously rescued and characterized [12]. The virus was propagated in 10-day-old specific pathogen-free embryonated chicken eggs (Charles River Laboratories, Wilmington, MA, USA). Eggs were incubated at 37 °C for 72 h and subsequently cooled at 4 °C overnight. Allantoic fluid was harvested and clarified by centrifugation at 2000× g for 10 min at 4 °C using a Sorvall Legend RT Plus Refrigerated Benchtop Centrifuge (Thermo Fisher Scientific, Waltham, MA, USA). Viral replication was confirmed by hemagglutination (HA) assays with turkey red blood cells (LAMPIRE Biological Laboratories, Pipersville, PA, USA). HA-positive allantoic fluids were pooled for virus inactivation and purification.

2.3. Inactivation of NDV-HXP-S Virus

As described previously [16], clarified allantoic fluid was mixed with 0.5 M disodium phosphate at a ratio of 38:1 (v/v). Ice-cold 2% β-propiolactone (BPL) (Sigma-Aldrich, Saint Louis, MO, USA; Cat# P5648) was added dropwise with continuous shaking to a final concentration of 0.05% BPL. The mix was incubated on ice for 30 min and then transferred to 37 °C. After a 2 h incubation, the allantoic fluid was clarified at 2000× g for 30 min at 4 °C using a Sorvall Legend RT Plus Refrigerated Benchtop Centrifuge (Thermo Fisher Scientific, Waltham, MA, USA).
To confirm inactivation, 10-day-old embryonated chicken eggs were inoculated with the inactivated allantoic fluid, incubated at 37 °C for 72 h, and then tested by an HA assay to confirm the absence of viral replication.

2.4. Purification of NDV-HXP-S Virus for Vaccination

The inactivated ancestral NDV-HXP-S virus present in clarified allantoic fluid was purified through a 20% sucrose cushion in 1× phosphate-buffered saline (PBS) (pH 7.4) by ultracentrifugation in a Beckman L7-65 ultracentrifuge at 25,000 rpm for 2 h at 4 °C using a Beckman SW28 rotor (Beckman Coulter, Brea, CA, USA). Supernatants were aspirated, and the resulting pellet was resuspended in 1× PBS (pH 7.4). The total protein concentration of the preparation was determined by the Pierce bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA, Cat# 23227).

2.5. Ethics Statement

Animal experiments were conducted under protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the Icahn School of Medicine at Mount Sinai (PROTO202000098, latest approval date 23 July 2025).

2.6. Mouse Immunization Experiments

Eight-week-old female BALB/c mice (Jackson Laboratories, Bar Harbor, ME, USA) were housed in a temperature-controlled biosafety level 2 facility under a 12 h light/dark cycle. Mice were vaccinated intramuscularly (IM) with 100 μL of purified inactivated NDV-HXP-S vaccine (50 μL per hind leg), with or without adjuvant. Three vaccine doses were tested: 1 μg, 0.1 μg, or 0.01 μg (total protein). All vaccinations followed a prime-boost regimen with a four-week interval. For adjuvanted formulations, AddaVax, AddaS03, or Alum were mixed with each vaccine dose at a 1:1 (v/v) ratio, and 10 μg of Quil-A was mixed with each vaccine dose.
Blood was collected 4 weeks after the prime dose via submandibular vein bleeding. Four weeks after the boost, mice were sedated by intraperitoneal (IP) injection with ~100 mg/kg ketamine hydrochloride (Dechra Veterinary Products, Overland Park, KS, USA) and ~20 mg/kg xylazine (AnaSed Injection, Akorn Animal Health, Lake Forest, IL, USA). Terminal blood was collected by cardiac puncture, followed by euthanasia in accordance with IACUC protocols. Serum was isolated from blood samples by centrifugation at 2800× g for 30 min at 4 °C using an Eppendorf centrifuge 5430R (Eppendorf, Enfield, CT, USA) and stored at −80 °C until processing.

2.7. Enzyme-Linked Immunosorbent Assays (ELISAs)

Immulon 4 HBX clear flat-bottom immuno nonsterile 96-well plates (Thermo Fisher Scientific, Waltham, MA, USA, Cat# 3855) were coated overnight at 4 °C with 50 μL/well of the indicated recombinant protein at a concentration of 2 µg/mL in 1× coating buffer (SeraCare Life Sciences, Milford, MA, USA, Cat# 5150-0014). Plates were washed with 1× PBS (pH 7.4) containing 0.1% (v/v) Tween-20 (PBST) and incubated with blocking solution (3% goat serum, 0.5% nonfat dried milk powder, 96.5% PBST) for 1 h at room temperature (RT). Then, three-fold serial dilutions of individual serum samples prepared in blocking solution were added to the plates and incubated for 2 h at RT. Plates were washed with PBST and incubated with sheep anti-mouse IgG horseradish peroxidase (HRP) secondary antibody (Cytiva, Marlborough, MA, USA, Cat# NA931), which was diluted in blocking solution. After 1 h incubation at RT, plates were washed with PBST and developed using SigmaFast o-phenylenediamine dihydrochloride substrate (Sigma-Aldrich, Saint Louis, MO, USA, Cat# P9187) for 10 min. The reaction was stopped with 3 M hydrochloric acid. Absorbance at 492 nm was measured using a FilterMax F3 multi-mode microplate reader (Molecular Devices, San Jose, CA, USA).
For each ELISA plate, the cutoff for endpoint titer was defined as the mean absorbance of blank wells plus three standard deviations. Endpoint titers were calculated using GraphPad Prism version 10.0.2 for Mac OS X (GraphPad Software, Boston, MA, USA; www.graphpad.com).

2.8. Microneutralization Assay

Replication-competent vesicular stomatitis virus (rcVSV) carrying an enhanced green fluorescent protein (eGFP) reporter gene and expressing the SARS-CoV-2 spike from either the ancestral strain, or important VOCs (Alpha, Beta, Delta, BA.1, BA.5, BQ.1.1, or XBB.1.5) in place of VSV glycoprotein (G protein) were produced as described previously [56]. Flat-bottom 96-well plates (Corning Inc., Corning, NY, USA, Ca# 353072) were seeded with 2 × 104 BHK-hACE2 cells/well and incubated overnight. The next day, pooled serum samples from each group were heat-inactivated at 56 °C for 30 min prior to use. The different viruses were pre-mixed with four-fold serially diluted serum (starting at 1:5) in DMEM supplemented with 10% FBS and 1% Pen Strep, and then incubated for 15 min at RT. The virus-serum mixtures were transferred onto the BHK-hACE2 cell plates. Cells infected in the absence of serum (“no serum” control) were included as a reference. At 12 h post-infection (hpi), plates were scanned using the Nexcelom Celigo S Image Cytometer BFFL 5C-AV (Nexcelom Biosciences, Lawrence, MA, USA), and infected eGFP-positive cells were quantified using Celigo software (version 5.5.0.0). EGFP counts for each serum-treated condition were normalized to the “no serum” control, which was set as 100% infection. The inhibitory dilution at which 50% neutralization is achieved (ID50) was determined by analyzing the normalized values using GraphPad Prism (version 10.0.2 for Mac OS X; GraphPad Software, Boston, MA, USA; www.graphpad.com) with the “log(inhibitor) vs. normalized response-variable slope” model.

2.9. Statistics

Statistical significance between the unadjuvanted group and each adjuvanted group was assessed using the Mann–Whitney–Wilcoxon test in GraphPad Prism (version 10.0.2 for Mac OS X; GraphPad Software, Boston, MA, USA; www.graphpad.com). All statistical tests were two-sided, and a p-value ≤ 0.05 was considered statistically significant.

3. Results

3.1. AddaVax, AddaS03, and Alum Significantly Enhance IgG Titers Against the Ancestral SARS-CoV-2 Spike

To assess the magnitude and breadth of antibody responses elicited by the different adjuvanted inactivated NDV-HXP-S vaccines, we performed a dose-escalation study with or without adjuvants. An NDV-HXP-S vaccine expressing the full-length ancestral SARS-CoV-2 spike was used as a reference to evaluate cross-reactive immune responses.
The inactivated purified NDV-HXP-S vaccine was administered IM to BALB/c mice in a prime-boost regimen with a 4-week interval (Figure 2A). As shown in Figure 2B, mice were immunized with 1, 0.1, or 0.01 µg of vaccine, either alone (groups 1–3) or formulated with AddaVax (groups 4–6), AddaS03 (groups 7–9), Alum (groups 10–12), or Quil-A (groups 13–15). An unvaccinated control group received PBS only (group 16). Mice were bled 4 weeks post-prime and terminally bled 4 weeks post-boost (Figure 2A). IgG responses against the full-length ancestral spike protein were measured by ELISA.
After a single immunization, the unadjuvanted vaccine induced a geometric mean IgG endpoint titer of ~2 × 104 at 1 µg. The reduction in unadjuvanted vaccine to a 0.1 µg dose modestly reduced antibody titers, while a decrease to a 0.01 µg dose resulted in a significant reduction (Figure 2C, solid white bars). Compared to the unadjuvanted vaccine, AddaVax did not enhance IgG responses at 1 µg but significantly increased titers at lower doses (Figure 2C, solid blue vs. solid white bars). In contrast, AddaS03 significantly boosted titers at 1 µg but showed no effect at lower doses (Figure 2C, solid red vs. solid white bars). Alum was the most effective adjuvant after priming, substantially increasing IgG titers across all doses tested (Figure 2C, solid green vs. solid white bars).
Following the booster dose, the unadjuvanted vaccine elicited significantly higher IgG titers compared to post-prime levels (Figure 2C solid white bars vs. hatched white bars). After the boost, AddaVax increased titers by ~10-fold across all vaccine doses tested relative to the unadjuvanted vaccine (Figure 2C, hatched blue vs. hatched white bars). AddaS03 (Figure 2C, hatched red bars) and Alum (Figure 2C, hatched green bars) also significantly improved antibody responses at 1 µg and 0.1 µg as compared to the unadjuvanted vaccine, though their effects were moderate at 0.01 µg (Figure 2C).
In contrast, formulations with Quil-A did not further enhance IgG titers at either timepoint (Figure 2C, solid and hatched purple bars).
These results suggest that AddaVax, AddaS03, and Alum are promising adjuvants for improving the IgG response against the ancestral spike protein of SARS-CoV-2 after priming or boosting with the inactivated NDV-HXP-S.

3.2. The Unadjuvanted Inactivated NDV-HXP-S Vaccine Induces a Predominantly RBD-Specific Antibody Response

We next characterized the antibody responses against different spike domains in the absence of adjuvants. Using post-boost sera, we measured IgG titers against S1, S2, the NTD, and the RBD of the ancestral spike protein, as well as the corresponding domains from three phylogenetically different VOCs (Beta, Delta, and BA.1) (Figure 3A).
Reducing the vaccine dose of the unadjuvanted NDV-HXP-S vaccine revealed that S1 and RBD are the most dominant domains when antibody responses to the ancestral spike are measured (Figure 3B). Similar results were observed when the immune responses against different domains of VOCs were measured (Figure 3C–E).
Together, these findings indicate that the unadjuvanted NDV-HXP-S vaccine primarily induces antibodies targeting S1, particularly the RBD, while responses to S2 and NTD are subdominant.

3.3. Adjuvant Selection Differentially Influenced Domain-Specific Antibody Responses Induced by the Inactivated NDV-HXP-S Vaccine

Next, we evaluated how adjuvants influenced antibody responses against different domains of the spike. At the highest vaccine dose (1 µg), AddaVax, AddaS03, and Alum significantly increased S1-specific titers across all variants, whereas Quil-A was less effective (Figure 4A). At lower vaccine doses, the boosting effect of AddaS03 and Alum on S1 responses was modest for most viruses tested. Notably, only AddaVax consistently induced a significant enhancement of cross-reactive S1 antibodies against all three VOCs (Beta, Delta, and BA.1) at low doses. In contrast, Quil-A tended to reduce titers towards S1 in most conditions as the vaccine dose decreased (Figure 4A).
For the S2 subunit, Alum was the only adjuvant to consistently induce a strong boost in antibody responses across all tested conditions. However, AddaVax, AddaS03, and Quil-A showed variable effects, significantly boosting antibody responses under select conditions depending on dose and the VOC tested (Figure 4B).
For the RBD, AddaS03 was most effective at 1 µg, while AddaVax performed best at 0.01 µg. On the other hand, Alum and Quil-A had mostly moderate effects on the RBD response (Figure 4C). For the NTD, Alum was the most consistent enhancer across all tested conditions, while AddaS03 and Quil-A boosted responses only at doses ≥ 0.1 µg. AddaVax effectively enhanced NTD responses at the highest vaccine dose (1 µg), but at lower doses consistently boosted antibody titers only against the Delta and BA.1 NTDs (Figure 4D).
In summary, these results indicate that AddaVax, AddaS03, and Alum were the most effective adjuvants for boosting IgG responses against different spike domains of SARS-CoV-2, with their potency varying depending on both the domain and the vaccine dose. Interestingly, Alum was the most effective for enhancing S2- and NTD-specific antibody responses.

3.4. AddaVax, AddaS03, and Alum Are the Most Effective Adjuvants for Boosting Cross-Neutralizing Antibodies

Neutralizing antibodies are a key correlate of protection against SARS-CoV-2. We therefore evaluated the neutralizing activity of vaccine-induced antibodies in post-boost sera using an rcVSV engineered to express eGFP and the SARS-CoV-2 spike (rcVSV-eGFP-CoV2-S). For this assay, we tested viruses carrying the ancestral spike or those from major variants of concern (Alpha, Beta, Delta, BA.1, BA.5, BQ.1.1, and XBB.1.5). Viruses were incubated with pooled, heat-inactivated sera, and neutralization was measured in BHK-hACE2 cells. At 12 h post-infection, ID50 values were determined. Pooled sera from each group were selected for this assay to evaluate group-level neutralization estimates as an initial screening of the adjuvant candidates.
At a 1 µg dose, the unadjuvanted vaccine induced comparable neutralization titers against the ancestral, Alpha, Beta, and Delta spikes, but titers against BA.1 and BA.5 were ~10-fold lower (Figure 5). As the dose decreased, neutralization elicited by the unadjuvanted vaccine declined, and at 0.01 µg activity, it was largely restricted to the ancestral and Alpha variants. Cross-neutralization of BQ.1.1 and XBB.1.5 was undetectable at all doses (Figure 5).
Adjuvants markedly improved neutralizing responses. At 1 and 0.1 µg, AddaVax, AddaS03, Alum, and Quil-A significantly enhanced neutralization against most variants. At the lowest vaccine dose (0.01 µg), only AddaVax, AddaS03, and Alum sustained enhanced neutralization across several variants, while Quil-A had little effect. Similar to the unadjuvanted vaccine, cross-neutralization of BQ.1.1 and XBB.1.5 remained minimal across all adjuvant conditions (Figure 5).
In summary, AddaVax, AddaS03, and Alum were the most effective adjuvants for enhancing cross-neutralizing antibodies, although they did not broaden responses to all immune-evasive VOCs tested.

4. Discussion

In this study, we performed an initial systematic evaluation of the breadth of antibody responses elicited by the inactivated NDV-HXP-S vaccine formulated with various adjuvants to identify candidates that best broaden antibody responses. We specifically assessed responses to an NDV-HXP-S vaccine expressing the ancestral SARS-CoV-2 spike against antigenically distinct VOCs.
Consistent with previous reports, a prime-boost regimen with the unadjuvanted vaccine induced high serum antibody levels in mice, even at a low antigen dose of 0.01 µg, confirming the strong intrinsic immunogenicity of the NDV-HXP-S vaccine. The antibodies elicited by the NDV-HXP-S vaccine were primarily targeted to the RBD located in the S1 subunit. Cross-reactive responses to Beta, Delta, and BA.1 domains were also dominated by RBD.
This aligns with prior work in humans, where inactivated NDV-HXP-S vaccination elicited a strongly RBD-focused antibody profile with limited S2 reactivity [57]. This bias has been suggested to result from limited accessibility to NTD and S2 epitopes on HXP-S, either due to (1) steric hindrance from the densely packed NDV hemagglutinin–neuraminidase (HN) and F proteins, which favor B cell receptor access to the RBD located at the top of the HXP-S trimer, or (2) the pre-fusion-stabilized HXP-S design masking key S2 and NTD epitopes that are only exposed in the post-fusion conformation. A combination of these two mechanisms is also plausible [57].
Adjuvant formulation revealed that AddaVax, AddaS03, and Alum were the most effective compounds, each with specific strengths depending on vaccine dose and epitope specificity. For many conditions, the enhancing effects of the adjuvants were moderate, likely due to the high intrinsic immunogenicity of NDV-HXP-S. However, we found that AddaVax markedly increased IgG titers against the full-length spike at all doses after boosting, with particularly strong effects at 0.01 µg. AddaS03 and Alum boosted responses mainly at higher doses, suggesting a particular value for high-dose formulations such as those used in populations with weakened immune systems (e.g., older adults).
All three adjuvants, AddaVax, AddaS03, and Alum, enhanced antibody responses to the different spike domains of the ancestral, Beta, Delta, and BA.1 variants. Interestingly, Alum most strongly boosted S2- and NTD- specific antibodies, an attribute that is important for sustaining protection against emerging variants harboring extensive mutations in the RBD. These differences may result from the distinct adjuvant-antigen interactions, as well as the different innate immune activation and antigen presentation pathways promoted by each adjuvant [37,40,50]. This distinction suggests that different adjuvants may skew epitope targeting within the HXP-S protein and highlights the importance of adjuvant selection to improve the antibody response elicited by the vaccine.
In addition, neutralization assays further support the advantages of AddaVax, AddaS03, and Alum as promising components for adjuvanted formulations. Notably, these three adjuvants maintained neutralizing activity even at the lowest vaccine dose (0.01 µg) to a subset of phylogenetically different strains like Omicron BA.1, highlighting their capacity to extend protective responses under conditions of limited antigen availability. However, given that neutralization activity was not observed with highly immune-evasive VOCs such as BQ.1.1 and XBB.1.5, the combination of these adjuvants to NDV-HXP-S vaccines expressing the circulating VOCs [14,18] or multivalent formulations [13,17] might be needed to further extend the breadth of protection to more recent VOCs.
In contrast, Quil-A was less promising as a candidate adjuvant for the inactivated NDV-HXP-S vaccine. Quil-A improved binding and neutralization under select conditions but generally was less effective than AddaVax, AddaS03, and Alum. It is important to note that Quil-A was administered at the manufacturer-recommended mouse dose (≤15 µg/dose), which did not correspond to the composition or dose of human-use saponin-based adjuvants such as QS-21. Our findings, therefore, reflect mouse-optimized formulations only and are not intended to imply direct comparability to human vaccine adjuvant systems.
Study limitations include the use of pooled sera for neutralization, which obscures individual variability and the ability to perform formal statistical inference, the short follow-up period preventing assessment of humoral response durability, and the lack of cellular immunity analysis. Future work should address these limitations, assess adjuvant effects in multivalent NDV-HXP-S formulations and updated strains, and evaluate responses in pre-immune models. Additionally, the quantification of antibody quality measures such as affinity/dissociation kinetics, IgG subclasses, or Fc-mediated effector activity of the antibodies elicited by the adjuvanted vaccines would strengthen mechanistic interpretation and the relevance of adjuvant differences.
Taken together, our findings provide new guidance for future NDV-HXP-S vaccine design aimed at improving protection against continuously evolving VOCs. First, the strong RBD-focused immunodominance observed with the ancestral HXP-S highlights the need for adjuvant formulations to redirect antibody responses toward subdominant but more conserved epitopes, including the NTD and S2 subunit. Moreover, the preferential boosting of NTD- and S2-specific antibodies by Alum suggests that specific adjuvants can modulate epitope targeting of NDV-based vaccines and may complement next-generation HXP-S designs that improve accessibility of these regions. Second, our neutralization data against immune-evasive VOCs indicate that adjuvants alone are not sufficient to overcome extensive antigenic drift, supporting the incorporation of variant-specific spikes or multivalent antigen formulations expressing spikes from antigenically distinct lineages. Combining optimized adjuvants with multivalent or updated NDV-HXP-S antigens may provide synergistic benefits by simultaneously enhancing antibody magnitude, breadth, and epitope diversity, thereby increasing cross-protection against future variants. These insights emphasize that integrating antigen selection, multivalency, and adjuvant choice will be critical for sustaining the effectiveness of NDV-HXP-S–based vaccines in the context of ongoing SARS-CoV-2 evolution.

5. Conclusions

In summary, NDV-HXP-S vaccination induces strong RBD-focused antibody responses that can be broadened with selected adjuvants. Among those tested, AddaVax, AddaS03, and Alum markedly enhanced immunogenicity, with Alum most effective at boosting S2-specific responses associated with broad cross-neutralization. Quil-A was less beneficial or, in some instances, detrimental. These findings support further evaluation of Alum, AddaVax, and AddaS03 in next-generation vaccine formulations. Finally, future studies in humans will be critical to establish the clinical potential of these adjuvants and guide rational adjuvant selection for adjuvanted NDV-HXP-S vaccines with broader protection.

Author Contributions

Conceptualization, J.L.M.-G., P.P. and W.S.; Preparation of the vaccines, J.L.M.-G., and T.Y.L.; Experimental data, J.L.M.-G., T.Y.L., M.M., S.S., I.G.-D., A.A., M.T.H.; Resources, G.S., F.K., S.K., B.L., P.P., W.S.; Formal data analysis and curation, J.L.M.-G., P.P. and W.S.; Writing—original draft preparation, J.L.M.-G., P.P. and W.S.; Funding, P.P., and W.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by Icahn School of Medicine at Mount Sinai funding awarded to W.S. and partially by NIH Grants 2R01AI145870-06 and 75N93019C00051, awarded to P.P.

Institutional Review Board Statement

The animal study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at the Icahn School of Medicine at Mount Sinai (PROTO202000098, latest approval date 23 July 2025).

Data Availability Statement

All data are presented in the manuscript; requests for raw data may be submitted to the corresponding author.

Acknowledgments

The animal workflow shown in Figure 2A was created in BioRender. Martinez, J. (2025). https://BioRender.com/itv644n (accessed on 22 August 2025). We thank the contributors and originating laboratories of the GISAID initiative for generating and sharing the sequence data used in the phylogenetic tree presented in this study.

Conflicts of Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: P.P, F.K, and W.S have the patent “RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-CoV-2 SPIKE PROTEIN AND USES THEREOF” pending at The Icahn School of Medicine at Mount Sinai. Mount Sinai is seeking to commercialize this vaccine; therefore, the institution and its faculty inventors could benefit financially. Mount Sinai has spun out a company, CastleVax, to commercialize the NDV-based SARS-CoV.2 vaccine. P.P., F.K., and W.S. serve on the scientific advisory board of CastleVax and are listed as co-founders of the company. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Abbreviations

The following abbreviations are used in this manuscript:
SARS-CoV-2Severe acute respiratory syndrome coronavirus 2
aaAmino acids
ACE2Angiotensin-converting enzyme 2
AlumAlhydrogel adjuvant 2%
AS03Adjuvant System 03
BHKBaby hamster kidney
BHK-hACE2BHK cells stably expressing human ACE2
BPLβ-propiolactone
CTCytoplasmic tail
DMEMDulbecco’s modified Eagle’s medium
eGFPEnhanced green fluorescent protein
ELISAEnzyme-linked immunosorbent assay
FFusion protein
FBSFetal bovine serum
FPFusion peptide
G proteinGlycoprotein
GPOGovernment Pharmaceutical Organization
HAHemagglutination
HNHemagglutinin–neuraminidase
hpiHours post-infection
HRHeptapeptide repeat sequence
HRPHorseradish peroxidase
HXP-SHexapro-spike
IACUCInstitutional Animal Care and Use Committee
ID50Inhibitory dilution at which 50% neutralization is achieved
IMIntramuscularly
IPIntraperitoneal
NDVNewcastle disease virus
NTD N-terminal domain
PBSPhosphate-buffered saline
PBST1× PBS (pH 7.4) containing 0.1% (v/v) Tween-20
Pen Strep Penicillin plus streptomycin
RBD Receptor-binding domain
RBMReceptor-binding motif
rcVSVReplication-competent vesicular stomatitis virus
rcVSV-eGFP-CoV2-SReplication-competent VSV engineered to express a GFP reporter and a SARS-CoV-2 spike protein in place of the native VSV-G protein
TMTransmembrane domain
VOCsVariants of concern

References

  1. World Health Organization. Novel Coronavirus (2019-nCoV): Situation Report. 2020. Available online: https://iris.who.int/handle/10665/330760 (accessed on 21 July 2025).
  2. Boni, M.F.; Lemey, P.; Jiang, X.; Lam, T.T.Y.; Perry, B.W.; Castoe, T.A.; Rambaut, A.; Robertson, D.L. Evolutionary Origins of the SARS-CoV-2 Sarbecovirus Lineage Responsible for the COVID-19 Pandemic. Nat. Microbiol. 2020, 5, 1408–1417. [Google Scholar] [CrossRef]
  3. Naveed, N.; Ahmad, K.; Majeed, H.; Qureshi, K.; Ahmad, I.; Awan, M.F.; Iftikhar, T.; Ahmad, S.; Noreen, F.; Amin, M.A.; et al. The Global Impact of COVID-19: A Comprehensive Analysis of Its Effects on Various Aspects of Life. Toxicol. Res. 2024, 13, tfae045. [Google Scholar] [CrossRef]
  4. Wang, M.Y.; Zhao, R.; Gao, L.J.; Gao, X.F.; Wang, D.P.; Cao, J.M. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front. Cell. Infect. Microbiol. 2020, 10, 587269. [Google Scholar] [CrossRef]
  5. Duan, L.; Zheng, Q.; Zhang, H.; Niu, Y.; Lou, Y.; Wang, H. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Front. Immunol. 2020, 11, 576622. [Google Scholar] [CrossRef]
  6. Letko, M.; Marzi, A.; Munster, V. Functional Assessment of Cell Entry and Receptor Usage for SARS-CoV-2 and Other Lineage B Betacoronaviruses. Nat. Microbiol. 2020, 5, 562–569. [Google Scholar] [CrossRef]
  7. Liu, L.; Wang, P.; Nair, M.S.; Yu, J.; Rapp, M.; Wang, Q.; Luo, Y.; Chan, J.F.W.; Sahi, V.; Figueroa, A.; et al. Potent Neutralizing Antibodies against Multiple Epitopes on SARS-CoV-2 Spike. Nature 2020, 584, 450–456. [Google Scholar] [CrossRef]
  8. Andreano, E.; Nicastri, E.; Paciello, I.; Pileri, P.; Manganaro, N.; Piccini, G.; Manenti, A.; Pantano, E.; Kabanova, A.; Troisi, M.; et al. Extremely Potent Human Monoclonal Antibodies from COVID-19 Convalescent Patients. Cell 2021, 184, 1821–1835.e16. [Google Scholar] [CrossRef] [PubMed]
  9. Brouwer, P.J.M.; Caniels, T.G.; van der Straten, K.; Snitselaar, J.L.; Aldon, Y.; Bangaru, S.; Torres, J.L.; Okba, N.M.A.; Claireaux, M.; Kerster, G.; et al. Potent Neutralizing Antibodies from COVID-19 Patients Define Multiple Targets of Vulnerability. Science 2020, 369, 643–650. [Google Scholar] [CrossRef] [PubMed]
  10. Dejnirattisai, W.; Zhou, D.; Ginn, H.M.; Duyvesteyn, H.M.E.; Supasa, P.; Case, J.B.; Zhao, Y.; Walter, T.S.; Mentzer, A.J.; Liu, C.; et al. The Antigenic Anatomy of SARS-CoV-2 Receptor Binding Domain. Cell 2021, 184, 2183–2200.e22. [Google Scholar] [CrossRef] [PubMed]
  11. Chen, Y.; Zhao, X.; Zhou, H.; Zhu, H.; Jiang, S.; Wang, P. Broadly Neutralizing Antibodies to SARS-CoV-2 and Other Human Coronaviruses. Nat. Rev. Immunol. 2022, 23, 189–199. [Google Scholar] [CrossRef]
  12. Sun, W.; Liu, Y.; Amanat, F.; González-Domínguez, I.; McCroskery, S.; Slamanig, S.; Coughlan, L.; Rosado, V.; Lemus, N.; Jangra, S.; et al. A Newcastle Disease Virus Expressing a Stabilized Spike Protein of SARS-CoV-2 Induces Protective Immune Responses. Nat. Commun. 2021, 12, 6197. [Google Scholar] [CrossRef]
  13. González-Domínguez, I.; Martínez, J.L.; Slamanig, S.; Lemus, N.; Liu, Y.; Lai, T.Y.; Carreño, J.M.; Singh, G.; Singh, G.; Schotsaert, M.; et al. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiol. Spectr. 2022, 10, e0153822. [Google Scholar] [CrossRef]
  14. Slamanig, S.; Lemus, N.; Lai, T.Y.; Singh, G.; Mishra, M.; Abdeljawad, A.; Boza, M.; Dolange, V.; Singh, G.; Lee, B.; et al. A Single Immunization with Intranasal Newcastle Disease Virus (NDV)-Based XBB.1.5 Variant Vaccine Reduces Disease and Transmission in Animals against Matched-Variant Challenge. Vaccine 2025, 45, 126586. [Google Scholar] [CrossRef]
  15. Sun, W.; Leist, S.R.; McCroskery, S.; Liu, Y.; Slamanig, S.; Oliva, J.; Amanat, F.; Schäfer, A.; Dinnon, K.H.; García-Sastre, A.; et al. Newcastle Disease Virus (NDV) Expressing the Spike Protein of SARS-CoV-2 as a Live Virus Vaccine Candidate. eBioMedicine 2020, 62, 103132. [Google Scholar] [CrossRef]
  16. Sun, W.; McCroskery, S.; Liu, W.C.; Leist, S.R.; Liu, Y.; Albrecht, R.A.; Slamanig, S.; Oliva, J.; Amanat, F.; Schäfer, A.; et al. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines 2020, 8, 771. [Google Scholar] [CrossRef] [PubMed]
  17. González-Domínguez, I.; Abdeljawad, A.; Lai, T.Y.; Boza, M.; McCroskery, S.; Lemus, N.; Slamanig, S.; Singh, G.; Warang, P.; Yellin, T.; et al. Mucosal Multivalent NDV-Based Vaccine Provides Cross-Reactive Immune Responses against SARS-CoV-2 Variants in Animal Models. Front. Immunol. 2025, 16, 1524477. [Google Scholar] [CrossRef]
  18. Slamanig, S.; González-Domínguez, I.; Chang, L.A.; Lemus, N.; Lai, T.Y.; Martínez, J.L.; Singh, G.; Dolange, V.; Abdeljawad, A.; Kowdle, S.; et al. Intranasal SARS-CoV-2 Omicron Variant Vaccines Elicit Humoral and Cellular Mucosal Immunity in Female Mice. eBioMedicine 2024, 105, 105185. [Google Scholar] [CrossRef] [PubMed]
  19. Ponce-de-León, S.; Torres, M.; Soto-Ramírez, L.E.; Calva, J.J.; Santillán-Doherty, P.; Carranza-Salazar, D.E.; Carreño, J.M.; Carranza, C.; Juárez, E.; Carreto-Binaghi, L.E.; et al. Interim Safety and Immunogenicity Results from an NDV-Based COVID-19 Vaccine Phase I Trial in Mexico. NPJ Vaccines 2023, 8, 67. [Google Scholar] [CrossRef]
  20. Pitisuttithum, P.; Luvira, V.; Lawpoolsri, S.; Muangnoicharoen, S.; Kamolratanakul, S.; Sivakorn, C.; Narakorn, P.; Surichan, S.; Prangpratanporn, S.; Puksuriwong, S.; et al. Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1 Trial. eClinicalMedicine 2022, 45, 101323. [Google Scholar] [CrossRef]
  21. Duc Dang, A.; Dinh Vu, T.; Hai Vu, H.; Thanh Ta, V.; Thi Van Pham, A.; Thi Ngoc Dang, M.; Van Le, B.; Huu Duong, T.; Van Nguyen, D.; Lawpoolsri, S.; et al. Safety and Immunogenicity of an Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam. Vaccine 2022, 40, 3621–3632. [Google Scholar] [CrossRef]
  22. Peixoto de Miranda, É.J.F.; Calado, R.T.; Boulos, F.C.; de Sousa Moreira, J.A.; Machado, F.F.; Almeida, M.A.A.L.D.S.; Da Rocha, M.C.O.; Infante, V.; Mercer, L.D.; Hjorth, R.; et al. Safety and Immunogenicity of an Inactivated Recombinant New-castle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Results of a Randomized Vaccine-Controlled Phase I ADAPTCOV Trial in Brazil. Vaccine 2025, 52, 126680. [Google Scholar] [CrossRef]
  23. Government Pharmaceutical Organization (GPO). GPO Announced an Emergency Use Authorization of the COVID-19 Vaccine as a Booster Dose After a Successful Clinical Trial Phase 3. Available online: https://www.gpo.or.th/post/x4ql6u9g-1730730563688 (accessed on 22 July 2025).
  24. Comisión Federal para la Protección contra Riesgos Sanitarios. Cofepris Aprueba la Vacuna Mexicana Patria Contra COVID-19, Comunicado 79/2024. Available online: https://www.gob.mx/cofepris/articulos/cofepris-aprueba-la-vacuna-mexicana-patria-contra-covid-19#:~:text=El%20equipo%20multidisciplinario%20de%20dictamen,las%20instituciones%20p%C3%BAblicas%20que%20conforman (accessed on 22 July 2025).
  25. Liu, Y.; Liu, J.; Xia, H.; Zhang, X.; Fontes-Garfias, C.R.; Swanson, K.A.; Cai, H.; Sarkar, R.; Chen, W.; Cutler, M.; et al. Neutralizing Activity of BNT162b2-Elicited Serum. N. Engl. J. Med. 2021, 384, 1466–1468. [Google Scholar] [CrossRef] [PubMed]
  26. Planas, D.; Veyer, D.; Baidaliuk, A.; Staropoli, I.; Guivel-Benhassine, F.; Rajah, M.M.; Planchais, C.; Porrot, F.; Robillard, N.; Puech, J.; et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021, 596, 276–280. [Google Scholar] [CrossRef]
  27. Cao, Y.; Wang, J.; Jian, F.; Xiao, T.; Song, W.; Yisimayi, A.; Huang, W.; Li, Q.; Wang, P.; An, R.; et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2022, 602, 657–663. [Google Scholar] [CrossRef]
  28. Starr, T.N.; Greaney, A.J.; Addetia, A.; Hannon, W.W.; Choudhary, M.C.; Dingens, A.S.; Li, J.Z.; Bloom, J.D. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 2021, 371, 850–854. [Google Scholar] [CrossRef]
  29. Greaney, A.J.; Starr, T.N.; Gilchuk, P.; Zost, S.J.; Binshtein, E.; Loes, A.N.; Hilton, S.K.; Huddleston, J.; Eguia, R.; Crawford, K.H.D.; et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe 2021, 29, 44–57.e9. [Google Scholar] [CrossRef]
  30. Cerutti, G.; Guo, Y.; Zhou, T.; Gorman, J.; Lee, M.; Rapp, M.; Reddem, E.R.; Yu, J.; Bahna, F.; Bimela, J.; et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 2021, 29, 819–833.e7. [Google Scholar] [CrossRef] [PubMed]
  31. Chi, X.; Yan, R.; Zhang, J.; Zhang, G.; Zhang, Y.; Hao, M.; Zhang, Z.; Fan, P.; Dong, Y.; Yang, Y.; et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 2020, 369, 650–655. [Google Scholar] [CrossRef]
  32. McCallum, M.; De Marco, A.; Lempp, F.A.; Tortorici, M.A.; Pinto, D.; Walls, A.C.; Beltramello, M.; Chen, A.; Liu, Z.; Zatta, F.; et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 2021, 184, 2332–2347.e16. [Google Scholar] [CrossRef]
  33. Zhou, P.; Yuan, M.; Song, G.; Beutler, N.; Shaabani, N.; Huang, D.; He, W.T.; Zhu, X.; Callaghan, S.; Yong, P.; et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci Transl. Med. 2022, 14, eabi9215. [Google Scholar] [CrossRef] [PubMed]
  34. Pinto, D.; Sauer, M.M.; Czudnochowski, N.; Low, J.S.; Tortorici, M.A.; Housley, M.P.; Noack, J.; Walls, A.C.; Bowen, J.E.; Guarino, B.; et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 2021, 373, 1109–1116. [Google Scholar] [CrossRef]
  35. O’Hagan, D.T.; Ott, G.S.; De Gregorio, E.; Seubert, A. The Mechanism of Action of MF59—An Innately Attractive Adjuvant Formulation. Vaccine 2012, 30, 4341–4348. [Google Scholar] [CrossRef]
  36. Ott, G.; Barchfeld, G.L.; Chernoff, D.; Radhakrishnan, R.; van Hoogevest, P.; Van Nest, G. MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines. Pharm. Biotechnol. 1995, 6, 277–296. [Google Scholar] [CrossRef]
  37. O’Hagan, D.T.; Ott, G.S.; Van Nest, G.; Rappuoli, R.; Del Giudice, G. The History of MF59® Adjuvant: A Phoenix That Arose from the Ashes. Expert Rev. Vaccines 2013, 12, 13–30. [Google Scholar] [CrossRef]
  38. Morel, S.; Didierlaurent, A.; Bourguignon, P.; Delhaye, S.; Baras, B.; Jacob, V.; Planty, C.; Elouahabi, A.; Harvengt, P.; Carlsen, H.; et al. Adjuvant System AS03 Containing α-Tocopherol Modulates Innate Immune Response and Leads to Improved Adaptive Immunity. Vaccine 2011, 29, 2461–2473. [Google Scholar] [CrossRef] [PubMed]
  39. Cohet, C.; van der Most, R.; Bauchau, V.; Bekkat-Berkani, R.; Doherty, T.M.; Schuind, A.; Tavares Da Silva, F.; Rappuoli, R.; Garçon, N.; Innis, B.L. Safety of AS03-Adjuvanted Influenza Vaccines: A Review of the Evidence. Vaccine 2019, 37, 3006–3021. [Google Scholar] [CrossRef]
  40. Garçon, N.; Vaughn, D.W.; Didierlaurent, A.M. Development and Evaluation of AS03, an Adjuvant System Containing α-Tocopherol and Squalene in an Oil-in-Water Emulsion. Expert Rev. Vaccines 2012, 11, 349–366. [Google Scholar] [CrossRef]
  41. Pulendran, B.; S. Arunachalam, P.; O’Hagan, D.T. Emerging Concepts in the Science of Vaccine Adjuvants. Nat. Rev. Drug Discov. 2021, 20, 454–475. [Google Scholar] [CrossRef] [PubMed]
  42. Djurisic, S.; Jakobsen, J.C.; Petersen, S.B.; Kenfelt, M.; Klingenberg, S.L.; Gluud, C. Aluminium Adjuvants Used in Vaccines. Cochrane Database Syst. Rev. 2018, 2018, CD013086. [Google Scholar] [CrossRef]
  43. Dalsgaard, K. A Study of the Isolation and Characterization of the Saponin Quil a. Evaluation of Its Adjuvant Activity, with a Special Reference to the Application in the Vaccination of Cattle against Foot-and-Mouth Disease. Acta Vet. Scand. 1978, 8, 349–360. [Google Scholar] [CrossRef]
  44. Dalsgaard, K. Saponin Adjuvants—III. Isolation of a Substance from Quillaja Saponaria Molina with Adjuvant Activity in Foot-and-Mouth Disease Vaccines. Arch. Gesamte. Virusforsch. 1974, 44, 243–254. [Google Scholar] [CrossRef]
  45. Croda International Plc. Quil-A. Available online: https://www.crodapharma.com/en-gb/product-finder/product/4375-quil-a (accessed on 22 July 2025).
  46. Carnet, F.; Perrin-Cocon, L.; Paillot, R.; Lotteau, V.; Pronost, S.; Vidalain, P.O. An Inventory of Adjuvants Used for Vaccination in Horses: The Past, the Present and the Future. Vet. Res. 2023, 54, 18. [Google Scholar] [CrossRef] [PubMed]
  47. Tomaiuolo, S.; Jansen, W.; Soares Martins, S.; Devriendt, B.; Cox, E.; Mori, M. QuilA® Adjuvanted Coxevac® Sustains Th1-CD8+-Type Immunity and Increases Protection in Coxiella burnetii-Challenged Goats. npj Vaccines 2023, 8, 17. [Google Scholar] [CrossRef]
  48. Martin, L.B.B.; Kikuchi, S.; Rejzek, M.; Owen, C.; Reed, J.; Orme, A.; Misra, R.C.; El-Demerdash, A.; Hill, L.; Hodgson, H.; et al. Complete Biosynthesis of the Potent Vaccine Adjuvant QS-21. Nat. Chem. Biol. 2024, 20, 493–502. [Google Scholar] [CrossRef]
  49. Calabro, S.; Tortoli, M.; Baudner, B.C.; Pacitto, A.; Cortese, M.; O’Hagan, D.T.; De Gregorio, E.; Seubert, A.; Wack, A. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011, 29, 1812–1823. [Google Scholar] [CrossRef]
  50. Marrack, P.; McKee, A.S.; Munks, M.W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 2009, 9, 287–293. [Google Scholar] [CrossRef]
  51. Eisenbarth, S.C.; Colegio, O.R.; O’Connor, W.; Sutterwala, F.S.; Flavell, R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453, 1122–1126. [Google Scholar] [CrossRef] [PubMed]
  52. Kool, M.; Soullié, T.; van Nimwegen, M.; Willart, M.A.; Muskens, F.; Jung, S.; Hoogsteden, H.C.; Hammad, H.; Lambrecht, B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 2008, 205, 869–882. [Google Scholar] [CrossRef]
  53. Marty-Roix, R.; Vladimer, G.I.; Pouliot, K.; Weng, D.; Buglione-Corbett, R.; West, K.; MacMicking, J.D.; Chee, J.D.; Wang, S.; Lu, S.; et al. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants. J. Biol. Chem. 2016, 291, 1123–1136. [Google Scholar] [CrossRef] [PubMed]
  54. Amanat, F.; Stadlbauer, D.; Strohmeier, S.; Nguyen, T.H.O.; Chromikova, V.; McMahon, M.; Jiang, K.; Arunkumar, G.A.; Jurczyszak, D.; Polanco, J.; et al. A Serological Assay to Detect SARS-CoV-2 Seroconversion in Humans. Nat. Med. 2020, 26, 1033–1036. [Google Scholar] [CrossRef]
  55. Stadlbauer, D.; Amanat, F.; Chromikova, V.; Jiang, K.; Strohmeier, S.; Arunkumar, G.A.; Tan, J.; Bhavsar, D.; Capuano, C.; Kirkpatrick, E.; et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr. Protoc. Microbiol. 2020, 57, e100. [Google Scholar] [CrossRef] [PubMed]
  56. Ikegame, S.; Siddiquey, M.N.A.; Hung, C.T.; Haas, G.; Brambilla, L.; Oguntuyo, K.Y.; Kowdle, S.; Chiu, H.P.; Stevens, C.S.; Vilardo, A.E.; et al. Neutralizing Activity of Sputnik V Vaccine Sera against SARS-CoV-2 Variants. Nat. Commun. 2021, 12, 4598. [Google Scholar] [CrossRef] [PubMed]
  57. Carreño, J.M.; Raskin, A.; Singh, G.; Tcheou, J.; Kawabata, H.; Gleason, C.; Srivastava, K.; Vigdorovich, V.; Dambrauskas, N.; Gupta, S.L.; et al. An Inactivated NDV-HXP-S COVID-19 Vaccine Elicits a Higher Proportion of Neutralizing Antibodies in Humans than MRNA Vaccination. Sci. Transl. Med. 2023, 15, eabo2847. [Google Scholar] [CrossRef] [PubMed]
Vaccines 14 00138 g001
Figure 1. Domain organization of the SARS-CoV-2 spike protein. Primary structure of the SARS-CoV-2 spike indicating the positions of key domains: the signal peptide (1–13 aa), the N-terminal domain (NTD; 14–305 aa), the receptor-binding domain (RBD; 319–541 aa), the receptor-binding motif (RBM; 438–508 aa), the fusion peptide (FP; 816–834 aa), the heptapeptide repeat sequence domains HR1 (910–985 aa) and HR2 (1163–1211 aa), the transmembrane domain (TM; 1212–1234 aa), and the cytoplasmic tail (CT; 1235–1273 aa). Red arrowheads indicate the locations of the polybasic cleavage site S1/S2 and the S2′ cleavage site. Yellow arrowheads mark the positions of the six proline substitutions (F812P, A892P, A899P, A942P, K986P, and V987P) introduced into the HXP-S spike. The amino acid residue numbers corresponding to each domain are indicated.
Figure 1. Domain organization of the SARS-CoV-2 spike protein. Primary structure of the SARS-CoV-2 spike indicating the positions of key domains: the signal peptide (1–13 aa), the N-terminal domain (NTD; 14–305 aa), the receptor-binding domain (RBD; 319–541 aa), the receptor-binding motif (RBM; 438–508 aa), the fusion peptide (FP; 816–834 aa), the heptapeptide repeat sequence domains HR1 (910–985 aa) and HR2 (1163–1211 aa), the transmembrane domain (TM; 1212–1234 aa), and the cytoplasmic tail (CT; 1235–1273 aa). Red arrowheads indicate the locations of the polybasic cleavage site S1/S2 and the S2′ cleavage site. Yellow arrowheads mark the positions of the six proline substitutions (F812P, A892P, A899P, A942P, K986P, and V987P) introduced into the HXP-S spike. The amino acid residue numbers corresponding to each domain are indicated.
Vaccines 14 00138 g001
Vaccines 14 00138 g002
Figure 2. The inclusion of AddaVax, AddaS03, or Alum with the inactivated NDV-HXP-S vaccine elicits strong IgG responses in mice: (A,B) Immunization regimen and groups. (A) Eight-week-old female BALB/c mice received two intramuscular (IM) immunizations 4 weeks apart. Blood samples were collected 4 weeks after the prime and 4 weeks after the boost for in vitro serological assays. (B) Eighty mice, divided into 16 groups (n = 5) as described in the table, were immunized with 1, 0.1, or 0.01 μg of inactivated NDV-HXP-S vaccine bearing the ancestral spike, either without adjuvant (groups 1–3) or formulated with AddaVax (groups 4–6), AddaS03 (groups 7–9), Alum (groups 10–12), or Quil-A (groups 13–15). An unvaccinated control group, which received PBS, was also included (group 16). (C) Serum-specific IgG titers measured against the recombinant trimeric ancestral SARS-CoV-2 spike. Serum IgG titers after prime and boost against recombinant trimeric ancestral spike protein were measured by ELISA. Endpoint titers were determined for each sample, and geometric mean endpoint titers with geometric standard deviations are shown for each group. Gray circles represent titers from individual animals. Statistical significance was determined by the Mann–Whitney–Wilcoxon test. Asterisks indicate the significance level, with * = p-value ≤ 0.05, and ** = p-value ≤ 0.01. LOD: limit of detection. Figure 2A was created in BioRender. Martinez, J. (2025). https://BioRender.com/itv644n (accessed on 22 August 2025).
Figure 2. The inclusion of AddaVax, AddaS03, or Alum with the inactivated NDV-HXP-S vaccine elicits strong IgG responses in mice: (A,B) Immunization regimen and groups. (A) Eight-week-old female BALB/c mice received two intramuscular (IM) immunizations 4 weeks apart. Blood samples were collected 4 weeks after the prime and 4 weeks after the boost for in vitro serological assays. (B) Eighty mice, divided into 16 groups (n = 5) as described in the table, were immunized with 1, 0.1, or 0.01 μg of inactivated NDV-HXP-S vaccine bearing the ancestral spike, either without adjuvant (groups 1–3) or formulated with AddaVax (groups 4–6), AddaS03 (groups 7–9), Alum (groups 10–12), or Quil-A (groups 13–15). An unvaccinated control group, which received PBS, was also included (group 16). (C) Serum-specific IgG titers measured against the recombinant trimeric ancestral SARS-CoV-2 spike. Serum IgG titers after prime and boost against recombinant trimeric ancestral spike protein were measured by ELISA. Endpoint titers were determined for each sample, and geometric mean endpoint titers with geometric standard deviations are shown for each group. Gray circles represent titers from individual animals. Statistical significance was determined by the Mann–Whitney–Wilcoxon test. Asterisks indicate the significance level, with * = p-value ≤ 0.05, and ** = p-value ≤ 0.01. LOD: limit of detection. Figure 2A was created in BioRender. Martinez, J. (2025). https://BioRender.com/itv644n (accessed on 22 August 2025).
Vaccines 14 00138 g002
Vaccines 14 00138 g003
Figure 3. The unadjuvanted inactivated NDV-HXP-S vaccine elicits an antibody response predominantly directed toward S1 and the RBD: (A) Unrooted phylogenetic tree of SARS-CoV-2 evolution. The tree was constructed using nextstrain/ncov with 3356 genome sequences from the GISAID dataset, sampled between December 2019 and August 2025. Adapted from https://nextstrain.org/ncov/gisaid/global (accessed 11 August 2025). Red boxes indicate the VOCs selected for evaluation of cross-reactive antibody responses by ELISA. Domain-specific serum IgG titers measured 4 weeks after the boost against the recombinant spike domains of the ancestral (B), Beta (C), Delta (D), and BA.1 (E) variants were determined by ELISA. Endpoint titers were calculated for each sample. Geometric mean endpoint titers ± geometric standard deviation are shown for each group (n = 5). Gray circles represent individual animals. Statistical significance was determined by the Mann–Whitney–Wilcoxon test. Asterisks indicate the significance level, with * = p-value ≤ 0.05, and ** = p-value ≤ 0.01. LOD: limit of detection.
Figure 3. The unadjuvanted inactivated NDV-HXP-S vaccine elicits an antibody response predominantly directed toward S1 and the RBD: (A) Unrooted phylogenetic tree of SARS-CoV-2 evolution. The tree was constructed using nextstrain/ncov with 3356 genome sequences from the GISAID dataset, sampled between December 2019 and August 2025. Adapted from https://nextstrain.org/ncov/gisaid/global (accessed 11 August 2025). Red boxes indicate the VOCs selected for evaluation of cross-reactive antibody responses by ELISA. Domain-specific serum IgG titers measured 4 weeks after the boost against the recombinant spike domains of the ancestral (B), Beta (C), Delta (D), and BA.1 (E) variants were determined by ELISA. Endpoint titers were calculated for each sample. Geometric mean endpoint titers ± geometric standard deviation are shown for each group (n = 5). Gray circles represent individual animals. Statistical significance was determined by the Mann–Whitney–Wilcoxon test. Asterisks indicate the significance level, with * = p-value ≤ 0.05, and ** = p-value ≤ 0.01. LOD: limit of detection.
Vaccines 14 00138 g003
Vaccines 14 00138 g004
Figure 4. Heatmaps representing the log2 fold-change in IgG titers against different spike domains between the unadjuvanted vaccine and adjuvanted conditions. Domain-specific serum IgG titers against S1 (A), S2 (B), RBD (C), and NTD (D) from the ancestral, Beta, Delta, and BA.1 variants were measured 4 weeks after the boost. Each row represents a different variant, and each column represents a different adjuvanted condition. Average endpoint titers were determined for each group (n = 5), and fold-change was calculated by dividing the average endpoint titer of each adjuvanted condition by that of the unadjuvanted vaccine. Numbers shown within the heatmaps correspond to the log2 fold-change calculated for each group. Vaccine doses are indicated on the left.
Figure 4. Heatmaps representing the log2 fold-change in IgG titers against different spike domains between the unadjuvanted vaccine and adjuvanted conditions. Domain-specific serum IgG titers against S1 (A), S2 (B), RBD (C), and NTD (D) from the ancestral, Beta, Delta, and BA.1 variants were measured 4 weeks after the boost. Each row represents a different variant, and each column represents a different adjuvanted condition. Average endpoint titers were determined for each group (n = 5), and fold-change was calculated by dividing the average endpoint titer of each adjuvanted condition by that of the unadjuvanted vaccine. Numbers shown within the heatmaps correspond to the log2 fold-change calculated for each group. Vaccine doses are indicated on the left.
Vaccines 14 00138 g004
Vaccines 14 00138 g005
Figure 5. AddaVax, AddaS03, and Alum increase cross-neutralizing antibody titers against multiple SARS-CoV-2 VOCs. Neutralization titers from pooled sera of each group were measured against rcVSV-eGFP-CoV2-S viruses bearing the ancestral spike or spike proteins from Alpha, Beta, Delta, BA.1, BA.5, BQ.1.1, or XBB.1.5. Experiments were performed in technical duplicates, and the ID50 was determined for each sample. (A) Neutralization profiles of pooled sera from each group against the ancestral rcVSV-eGFP-CoV-2-S. Dots represent the mean neutralization values of the technical duplicates used at each dilution, and error bars indicate standard deviations. (B) Heatmaps displaying the log-transformed ID50 values calculated from the neutralization profiles obtained across all conditions.
Figure 5. AddaVax, AddaS03, and Alum increase cross-neutralizing antibody titers against multiple SARS-CoV-2 VOCs. Neutralization titers from pooled sera of each group were measured against rcVSV-eGFP-CoV2-S viruses bearing the ancestral spike or spike proteins from Alpha, Beta, Delta, BA.1, BA.5, BQ.1.1, or XBB.1.5. Experiments were performed in technical duplicates, and the ID50 was determined for each sample. (A) Neutralization profiles of pooled sera from each group against the ancestral rcVSV-eGFP-CoV-2-S. Dots represent the mean neutralization values of the technical duplicates used at each dilution, and error bars indicate standard deviations. (B) Heatmaps displaying the log-transformed ID50 values calculated from the neutralization profiles obtained across all conditions.
Vaccines 14 00138 g005
Table 1. Proteins from SARS-CoV2 variants obtained from ACROBiosystems for the ELISA experiments.
Table 1. Proteins from SARS-CoV2 variants obtained from ACROBiosystems for the ELISA experiments.
VariantProteinCatalog Number
AncestralSARS-CoV-2 (COVID-19) S1 protein, His Tag (MALS verified)S1N-C52H3
AncestralSARS-CoV-2 (COVID-19) S2 protein, His TagS2N-C52H2
AncestralSARS-CoV-2 (COVID-19) S1 protein NTD, His TagS1D-C52H6
BetaSARS-CoV-2 S1 protein (L18F, D80A, D215G, LAL242-244del, R246I, K417N, E484K, N501Y, D614G), Fc TagS1D-C5256
BetaSARS-CoV-2 S2 protein (A701V), His TagS2N-C52Hc
BetaSARS-CoV-2 S1 protein NTD (L18F, D80A, D215G, 242-244del, R246I), His Tag (MALS verified)S1D-C52Hc
DeltaSARS-CoV-2 Spike S1 Protein (T19R, G142D, EF156-157del, R158G, L452R, T478K, D614G, P681R), His TagS1N-C52Hu
DeltaSARS-CoV-2 Spike NTD Protein (T19R, G142D, EF156-157del, R158G), His Tag (MALS verified)S1D-C52Hh
BA.1SARS-CoV-2 Spike S1 Protein, His Tag (B.1.1.529/Omicron)S1N-C52Ha
BA.1SARS-CoV-2 Spike S2 protein, His Tag (BA.1/Omicron)S2N-C52Hf
BA.1SARS-CoV-2 Spike NTD Protein, His Tag (B.1.1.529/Omicron) (MALS verified)SPD-C522d
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Martínez-Guevara, J.L.; Lai, T.Y.; Mishra, M.; Slamanig, S.; González-Domínguez, I.; Abdeljawad, A.; Hoang, M.T.; Singh, G.; Kowdle, S.; Lee, B.; et al. AddaVax, AddaS03, and Alum Effectively Enhance Cross-Reactive and Cross-Neutralizing Antibody Responses Against SARS-CoV-2 Induced by the Inactivated NDV-HXP-S Vaccine in Mice. Vaccines 2026, 14, 138. https://doi.org/10.3390/vaccines14020138

AMA Style

Martínez-Guevara JL, Lai TY, Mishra M, Slamanig S, González-Domínguez I, Abdeljawad A, Hoang MT, Singh G, Kowdle S, Lee B, et al. AddaVax, AddaS03, and Alum Effectively Enhance Cross-Reactive and Cross-Neutralizing Antibody Responses Against SARS-CoV-2 Induced by the Inactivated NDV-HXP-S Vaccine in Mice. Vaccines. 2026; 14(2):138. https://doi.org/10.3390/vaccines14020138

Chicago/Turabian Style

Martínez-Guevara, José Luis, Tsoi Ying Lai, Mitali Mishra, Stefan Slamanig, Irene González-Domínguez, Adam Abdeljawad, Minh Thu Hoang, Gagandeep Singh, Shreyas Kowdle, Benhur Lee, and et al. 2026. "AddaVax, AddaS03, and Alum Effectively Enhance Cross-Reactive and Cross-Neutralizing Antibody Responses Against SARS-CoV-2 Induced by the Inactivated NDV-HXP-S Vaccine in Mice" Vaccines 14, no. 2: 138. https://doi.org/10.3390/vaccines14020138

APA Style

Martínez-Guevara, J. L., Lai, T. Y., Mishra, M., Slamanig, S., González-Domínguez, I., Abdeljawad, A., Hoang, M. T., Singh, G., Kowdle, S., Lee, B., Krammer, F., Palese, P., & Sun, W. (2026). AddaVax, AddaS03, and Alum Effectively Enhance Cross-Reactive and Cross-Neutralizing Antibody Responses Against SARS-CoV-2 Induced by the Inactivated NDV-HXP-S Vaccine in Mice. Vaccines, 14(2), 138. https://doi.org/10.3390/vaccines14020138

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop